Samsung Biologics (207940.KS)

Executive Summary

Samsung Biologics, a leading global CDMO headquartered in Incheon, South Korea, continues to solidify its position as one of the world's largest biologics manufacturers by capacity. Backed by the Samsung Group, the company offers end-to-end services from cell line development to commercial production, serving top-tier pharmaceutical and biotech clients. As of 2026, Samsung Biologics operates four plants with a total capacity of over 600,000 liters, and its fifth plant is nearing completion, which will add approximately 180,000 liters of capacity. The company has consistently reported strong revenue growth, driven by increasing demand for biologics outsourcing and its reputation for quality, speed, and reliability. Recent financial performance reflects robust contract wins, including long-term deals with major global pharma companies, and operational efficiencies from scale. The CDMO market is expanding rapidly, and Samsung Biologics is well-positioned to capture a significant share, supported by its aggressive capacity expansion and technological investments in modalities like antibody-drug conjugates (ADCs) and biosimilars. Looking ahead, the company's focus on innovation, digital transformation, and sustainability is expected to sustain its competitive edge and drive further margin improvements.

Upcoming Catalysts (preview)

• H2 2026Commercial Operation of Plant 585% success
• Q3 2026Major Long-Term Supply Agreement with Top 10 Pharma70% success
• Q4 2026FDA Approval of New Manufacturing Site for ADC Production60% success